No abstract

Objectives: Current clinical guidelines recommend the use of cilostazol in the treatment of patients with infrainguinal peripheral arterial disease (PAD) who experience claudication. However, the role of cilostazol therapy in patients with advanced PAD and critical limb ischemia (CLI) remains unclear. Our objective was to conduct a meta-analysis of randomized controlled trials and cohort studies that evaluated the effect of cilostazol versus standard antiplatelet therapy on limb-related and arterial patency-related outcomes. We also reviewed studies that evaluated the effect of cilostazol on wound healing in patients with advanced PAD.